Key terms
About GENE
Genetic Technologies Ltd. operates as a molecular diagnostics company, which engages in the provision of molecular risk assessment tests for cancer. It operates through EasyDNA, AffinityDNA and GeneType/Corporate segments. The EasyDNA segment focuses on EasyDNA branded test sales and expenses. The AffinityDNA segment focuses on AffinityDNA branded test sales and expenses.The GeneType/Corporate segment includes the GeneType branded test sales and expenses, including corporate charges. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GENE news
Mar 26
8:57am ET
Genetic Technologies Boosts Capital with Radium Loan
Mar 25
8:35am ET
Genetic Technologies to develop most advanced comprehensive risk test
Mar 22
11:02am ET
Genetic Technologies announces ‘company’s most advanced risk assessment test’
Mar 22
8:27am ET
Genetic Technologies Unveils Revolutionary Risk Test
Feb 28
8:08am ET
Genetic Technologies to launch U.S. customer digital media sales campaign
Jan 31
8:12am ET
Genetic Technologies shares business update for Q2
Jan 05
8:02am ET
Genetic Technologies regains compliance with Nasdaq minimum bid price rule
No recent news articles are available for GENE
No recent press releases are available for GENE
GENE Financials
Key terms
Ad Feedback
GENE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GENE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range